The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
about
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerMicrovesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cellsMicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.Emerging protein kinase inhibitors for treating pancreatic cancer.Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).An in-silico approach to predict and exploit synthetic lethality in cancer metabolism.Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients.Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization.MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism
P2860
Q28075540-711D2FC2-2B9D-4CE3-9345-9A70E59AA5F8Q28468669-0422B847-B68E-404B-8825-755DA30814ECQ37642511-620ABFB0-B4FC-4BD4-951F-16980EEA427EQ37720259-9CC26BAD-F8CA-4746-8430-3CB1DB9DDF87Q39158411-BB881F7E-6D20-4F40-B523-6C2A0E649E37Q41363526-D234F0E9-AF37-4271-962F-FF0FA975DC36Q41632506-22735F1C-E737-4A1C-8CD1-5AFB78FFA4DCQ46235377-12CE5B63-0785-4FA5-BCFE-D64C45F83BFEQ47128811-F5FC78AA-6041-4709-A643-1C9E8CA598CFQ55105483-8A81700C-D56F-4567-B5E4-0B5078C54674Q57175017-6DE0FB41-598A-4451-8D93-CB7139125B7F
P2860
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The MEK1/2 Inhibitor Pimaserti ...... de Reductase Subunit-1 (RRM1).
@en
type
label
The MEK1/2 Inhibitor Pimaserti ...... de Reductase Subunit-1 (RRM1).
@en
prefLabel
The MEK1/2 Inhibitor Pimaserti ...... de Reductase Subunit-1 (RRM1).
@en
P2093
P1476
The MEK1/2 Inhibitor Pimaserti ...... de Reductase Subunit-1 (RRM1).
@en
P2093
Daniel Hochhauser
Eleonora Li Causi
Francesca Vena
John A Hartley
Samantha Goodstal
Thorsten Hagemann
P304
P356
10.1158/1078-0432.CCR-15-0485
P407
P577
2015-07-30T00:00:00Z